83-2271-30　［受注停止］KRIBIOLISA Liraglutide （Victoza） ELISA 1 x 96 wells　KBI5020

特徴

• Description：Enzyme Immunoassay for the Quantitative Estimation of Liraglutide in human serum and plasma.
• Liraglutide （NN2211） is a derivative of a human incretin （metabolic hormone）, glucagon-like peptide-1 （GLP-1） that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion.
• Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes.
• In 2015, Novo Nordisk began marketing a separate strength in the U.S.
• and E.U.
• under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one weight-related comorbid condition.
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The method employs a sandwich immunoassay for the determination of Liraglutide.
• The anti-Liraglutide Antibodies are coated on microtiter plate.
• Liraglutide standard and Liraglutide present in the samples will bind to coating antibody.
• Anti-GLP-1 antibody conjugated to HRP is then added which produces a soluble colored product after addition of TMB substrate.
• The enzyme reaction is stopped by dispensing of stop solution into the wells.
• The optical density （OD） of the solution at 450 nm is directly proportional to the amount of bound Liraglutide present in the standards or samples.